cancer gastritis.ppt
-
Upload
muhammad-nurman -
Category
Documents
-
view
7 -
download
1
Transcript of cancer gastritis.ppt
![Page 1: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/1.jpg)
Gastric Carcinoma
Vic Vernenkar, D.O.
St. Barnabas Hospital
Department of Surgery
![Page 2: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/2.jpg)
Background
Second most common cancer-related death. Korea, Japan, China, Taiwan high rates. 22,000 diagnosed annually in US. 14th most common cancer. Difficult to cure, as advanced disease. Most die of recurrent disease even after
resection for cure.
![Page 3: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/3.jpg)
![Page 4: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/4.jpg)
Anatomy
Stomach begins at GE junction, ends at duodenum.
3 parts- uppermost is cardia, largest part in middle is body, the last part is pylorus.
Cardia contains mucin producing cells. Fundus or body mucoid cells, chief cells,
parietal cells. Pylorus has mucin producing cells.
![Page 5: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/5.jpg)
Anatomy
Five layers: Mucosa, submucosa, muscular layer, subserosal layer, serosal layer.
Peritoneum of greater sac covers anterior surface
A portion of lesser sac drapes posteriorly over stomach.
The GE junction has limited serosal covering.
![Page 6: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/6.jpg)
Anatomy
The site of the lesion is classified on basis of relationship to long axis of stomach.
40% lower part 40% middle part 15% upper part 10% more than one part Recently the # of lesions proximally has
increased.
![Page 7: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/7.jpg)
![Page 8: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/8.jpg)
Pathophysiology
Understand vascular supply, allows for understanding of routes of spread.
Derived from celiac artery. Left gastric supplies upper right stomach. Right gastric off common hepatic- lower
portion. Right gastroepiploic -lower portion of
greater curve.
![Page 9: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/9.jpg)
Pathophysiology
Understanding lymphatic drainage can clarify nodal involvement.
Complex drainage Primarily along celiac axis. Minor drainage along splenic hilum,
suprapancreatic nodal groups, porta hepatis, and gastroduodenal areas
![Page 10: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/10.jpg)
Frequency
US: seventh leading cause of cancer deaths, with 22,000 diagnosed yearly, and 14,000 deaths.
Internationally: second most common cancer. Tremendous geographic variation, with highest death rates in Chile, Japan, and former USSR.
![Page 11: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/11.jpg)
Mortality and Morbidity
5-year survival for curative resections ranges from 30-50% for stage II disease and 10-25% in stage III.
High likelihood of systemic and local relapse.
Adjuvant therapy is offered . Operative mortality is less than 3% for
curative resections.
![Page 12: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/12.jpg)
Race
Higher in Asian countries. Japanese detect patients at very early stage,
patients appear to do quite well. In Asian studies, patients with resected stage II
and III disease have better outcomes than similar stages in the west.
Some believe this reflects a biologic difference between diseases in Asia and west.
Black race, low socioeconomic class.
![Page 13: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/13.jpg)
Sex, Age
Men>women Most are elderly at diagnosis. Median age
65 years. The ones that present in younger patients may represent a more aggressive variant.
Cigarettes
![Page 14: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/14.jpg)
History
Early disease has no symptoms, some patients with incidental complaints get an early diagnosis.
If symptoms, it reflects advanced disease; These may include indigestion, nausea, dysphagia, early satiety, anorexia, weight loss.
![Page 15: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/15.jpg)
History
Late complications include: pleural effusions, peritoneal effusions, GOO, GE obstruction, SBO, bleeding, jaundice, cachexia.
![Page 16: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/16.jpg)
Physical
All physical signs are late events. Too late for curative procedures. Palpable stomach with succussion splash,
hepatomegaly, Virchow nodes, sister MJ nodes, Blumer shelf, weight loss, pallor from bleeding and anemia.
![Page 17: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/17.jpg)
Etiology
Diet H. Pylori Previous stomach surgery Pernicious anemia Polyps(rarely a precursor) Atrophic gastritis Radiation, genetics
![Page 18: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/18.jpg)
Diet
Certain diets are implicated. Rich in pickled vegetables, salted fish,
excessive dietary salt, smoked meats. A diet that includes fruits and vegetables
rich in vitamin C may have a protective effect.
![Page 19: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/19.jpg)
Helicobacter
Implicated as precursor of gastric cancer. H. Pylori associated with atrophic gastritis,
and patients with a history of prolonged gastritis have a 6-fold increase in risk.
Particularly true of tumors of antrum, body, and fundus of stomach, but not in cardia.
![Page 20: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/20.jpg)
Previous Surgery
Implicated as risk factor, the rational being that previous gastric surgery alters normal pH of stomach.
Retrospective studies show that a small percentage of patients who have a gastric polyp removed have evidence of invasive carcinoma in the polyp.
Polyps may therefore be premalignant.
![Page 21: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/21.jpg)
Genetic Factors
Poorly understood Some familial aggregation exists
![Page 22: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/22.jpg)
Laboratory
Assists in determining optimal therapy. CBC identifies anemia, with may be caused
by bleeding, liver dysfunction, or poor nutrition.
30% have anemia. Electrolyte panels and LFTs are also
essential to better characterize patients clinical state.
![Page 23: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/23.jpg)
Imaging Studies
EGD: safe, simple, providing a permanent color photographic record.
Obtains tissue for diagnosis. UGI: detects large tumors, but only
occasionally detects extension into esophagus or duodenum, especially if small or submucosal.
![Page 24: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/24.jpg)
![Page 25: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/25.jpg)
![Page 26: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/26.jpg)
Imaging Studies
CXR: done to evaluate for metastases. CT scan or MRI of chest, abdomen, pelvis:
evaluate local disease process, and areas of spread. Some tumors are deemed unresectable based on the testing.
Accurately predicts stage 66-77%. Poor nodal status prediction.
![Page 27: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/27.jpg)
Endoscopic Ultrasound Endoscopic ultrasound: becoming extremely
useful as a staging tool, when CT fails to show T3, T4, or metastatic disease.
Used with neoadjuvant chemo to stratify pts Can achieve resolution of 0.1 mm. Cannot reliably distinguish between tumor and
fibrosis. Overall staging accuracy of 75% Poor for T2 lesions (38%) Better for T1(80%), T3 (90%)
![Page 28: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/28.jpg)
![Page 29: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/29.jpg)
![Page 30: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/30.jpg)
Histology
Adenocarcinoma 95% Lymphomas 2% Carcinoids 1% Adenocathomas 1% Squamous cell 1%
![Page 31: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/31.jpg)
Histology
Adenocarcinoma is classified according to the most unfavorable microscopic element present: tubular, papillary, mucinous, signet-ring cells.
Also identified by gross appearance: ulcerative, polypoid, scirrous, superficial spreading, multicentric, or Barrett ectopic.
Variety of other schemes: Borrmann, Lauren.
![Page 32: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/32.jpg)
Borrmann Classification
5 categories Type I: polypoid or fungating Type II: ulcerating lesions with elevated
borders Type III: ulceration with invasion of wall Type IV: diffuse infiltration Type V: cannot be classified
![Page 33: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/33.jpg)
Lauren System
Epidemic or endemic The intestinal, expansive epidemic type
gastric cancer is associated with atrophic gastritis, retained glandular structure, little invasiveness, sharp margins. It would be a Borrmann I or II.
![Page 34: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/34.jpg)
Lauren System
The epidemic or Borrmann I or II carries better prognosis, shows no family history.
The diffuse, infiltrative, endemic, is poorly differentiated, with dangerously deceptive margins, invades large areas of stomach. Younger patients, genetic factors, blood groups, and family history.
![Page 35: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/35.jpg)
Staging
Primary tumorTx- cannot be assessedT0- no evidenceTis- carcinoma in situ, no invasion of laminaT1- invades lamina propria or submucosaT2- invades muscularis or subserosaT3- penetrates serosa, no adjacent structureT4- invades adjacent structures
![Page 36: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/36.jpg)
Regional Lymph Nodes
NX- cannot be assessed
N0- no nodes
N1- mets in 1-6 regional nodes
N2- mets in 7-15 regional nodes
N3- mets in more than 15 regional nodes
![Page 37: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/37.jpg)
Distant Metastases
MX- cannot be assessed M0- no distant metastases M1-distant metastases
![Page 38: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/38.jpg)
Prognostic Features
Depth of invasion through gastric wall, presence or absence of regional lymph node involvement
The greater number of positive nodes, the greater the likelihood of local or systemic failure postoperatively
![Page 39: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/39.jpg)
Spread Patterns
Directly, via lymphatics, or hematogenously
Direct extension into omentum, pancreas, diaphragm, transverse colon, and duodenum.
If lesion extends beyond wall to a free peritoneal surface, peritoneal involvement is frequent.
![Page 40: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/40.jpg)
Spread Patterns
The visible gross lesion frequently underestimates true extent.
Abundant lymphatic channels in submucosal and subserosal layers allow for easy spread.
The submucosal plexus is prominent in esophagus, the subserosal plexus prominent in duodenum, which allows for proximal and distal spread.
Liver mets common, from hematogenous spread.
![Page 41: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/41.jpg)
![Page 42: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/42.jpg)
Laparoscopy
Inspect peritoneal surfaces, liver surface. Identification of advanced disease avoids
non-therapeutic laparotomy in 25%. Patients with small volume metastases in
peritoneum or liver have a life expectancy of 3-9 months, thus rarely benefit from palliative resection.
![Page 43: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/43.jpg)
Lymph Node Dissection AJCC: number rather than location of LN is
prognostic. Extent of dissection controversial. Nodal involvement indicates poor prognosis, and
more aggressive approaches to remove them are taking favor.
Ongoing trials regarding this in Europe. Critics argue that the apparent benefit associated
with extended LND reflects stage migration (each LN is reviewed more carefully).
![Page 44: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/44.jpg)
Residual Disease R Status
Tumor status following resection. Assigned based on pathology of margins. R0- no residual gross or microscopic
disease. R1- microscopic disease only. R2- gross residual disease. Long term survival only in R0 resection.
![Page 45: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/45.jpg)
“D” Nomenclature
Describes extent of resection and lymphadenectomy.
D1- removes all nodes within 3cm of tumor. D2- D1 plus hepatic, splenic, celiac, and left
gastric nodes. D3- D2 plus omentectomy, splenectomy, distal
pancreatectomy, clearance of porta hepatis nodes. Current standards include a D1 dissection only.
![Page 46: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/46.jpg)
Type of Surgery
In general most surgeons perform total gastrectomy ( if required for negative margins), esophagogastrectomy for tumors of the cardia and GE junction, and a subtotal gastrectomy for tumors of the distal stomach.
Similar 5 year rates for subtotal vs. total in tumors of distal stomach.
Extensive lymphatics require 5cm margin.
![Page 47: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/47.jpg)
Outcome
5-year survival for a curative resection is 30-50% for stage II disease, 10-25% for stage III disease.
Adjuvant therapy because of high incidence of local and systemic failure.
A recent Intergroup 0116 randomized study offers evidence of a survival benefit associated with postoperative chemoradiotherapy
![Page 48: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/48.jpg)
Complications
Mortality 1-2% Anastamotic leak, bleeding, ileus, transit
failure, cholecystitis, pancreatitis, pulmonary infections, and thromboembolism.
Late complications include dumping syndrome, vitamin B-12 deficiency, reflux esophagitis, osteoporosis.
![Page 49: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/49.jpg)
Adjuvant Therapy
Rationale is to provide additional loco-regional control.
Radiotherapy- studies show improved survival, lower rates of local recurrence when compared to surgery alone.
In unresectable patients, higher 4 year survival with mutimodal tx, in comparison to chemo alone.
![Page 50: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/50.jpg)
Chemotherapy
Numerous randomized clinical trials comparing combination chemotherapy in the adjuvant setting to surgery alone did not demonstrate a consistent survival benefit.
The most widely used regimen is 5-FU, doxorubicin, and mitomycin-c. The addition of leukovorin did not increase response rates.
![Page 51: cancer gastritis.ppt](https://reader034.fdocuments.in/reader034/viewer/2022052701/563db8a8550346aa9a95b939/html5/thumbnails/51.jpg)
Advanced Unresectable Disease
Surgery is for palliation, pain, allowing oral intake
Radiation provides relief from bleeding, obstruction and pain in 50-75%. Median duration of palliation is 4-18 months